Covid-19 to Serve as Platform for South African Vaccine Industry – BloombergQuint

(Bloomberg) —
The BioVac Institute, a state-backed South African vaccine company, plans to use a deal it won to manufacture coronavirus shots as a stepping stone toward developing an inoculation export industry in the country.
The contract with U.S.-based ImmunityBio Inc., which is conducting phase 1 vaccine trials in South Africa and the U.S., will allow BioVac to transform itself from a facility that merely packages and labels the shots to one that makes the raw materials, Morena Makhoana, BioVacs…

Click here to view the original article.